 Vaughn Browne
Concepts (176)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Altitude | 12 | 2020 | 463 | 1.190 |
Why?
| | Uterine Artery | 6 | 2020 | 74 | 0.900 |
Why?
| | Cardiac Tamponade | 1 | 2022 | 15 | 0.750 |
Why?
| | Regional Blood Flow | 3 | 2015 | 514 | 0.460 |
Why?
| | Fetal Growth Retardation | 5 | 2013 | 593 | 0.450 |
Why?
| | Fetal Hypoxia | 2 | 2015 | 56 | 0.430 |
Why?
| | Pre-Eclampsia | 2 | 2020 | 206 | 0.410 |
Why?
| | Fetal Development | 2 | 2015 | 298 | 0.360 |
Why?
| | Papillary Muscles | 4 | 2004 | 13 | 0.340 |
Why?
| | Fetus | 2 | 2015 | 804 | 0.340 |
Why?
| | Vascular Resistance | 2 | 2020 | 370 | 0.330 |
Why?
| | Biological Evolution | 1 | 2015 | 468 | 0.330 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2011 | 69 | 0.310 |
Why?
| | Hypoxia | 6 | 2017 | 1199 | 0.270 |
Why?
| | Myocardial Contraction | 3 | 1997 | 293 | 0.260 |
Why?
| | Pregnancy Complications | 3 | 2017 | 603 | 0.240 |
Why?
| | Ultrasonography | 4 | 2017 | 788 | 0.220 |
Why?
| | Point-of-Care Systems | 2 | 2017 | 189 | 0.210 |
Why?
| | Pregnancy | 13 | 2020 | 7216 | 0.210 |
Why?
| | Bolivia | 6 | 2017 | 63 | 0.200 |
Why?
| | Fetal Heart | 3 | 2004 | 56 | 0.200 |
Why?
| | Pregnancy-Associated Plasma Protein-A | 1 | 2020 | 14 | 0.150 |
Why?
| | Acclimatization | 2 | 2013 | 170 | 0.150 |
Why?
| | Birth Weight | 2 | 2014 | 517 | 0.150 |
Why?
| | Uterus | 1 | 2020 | 228 | 0.140 |
Why?
| | Altitude Sickness | 2 | 2013 | 141 | 0.130 |
Why?
| | Receptors, Adrenergic, beta | 1 | 1997 | 58 | 0.130 |
Why?
| | Paracentesis | 1 | 2017 | 16 | 0.130 |
Why?
| | Education, Premedical | 1 | 2016 | 5 | 0.120 |
Why?
| | Heart | 2 | 1997 | 626 | 0.120 |
Why?
| | Gestational Age | 5 | 2014 | 990 | 0.120 |
Why?
| | Receptors, Erythropoietin | 1 | 2017 | 21 | 0.120 |
Why?
| | Ultrasonics | 1 | 2016 | 50 | 0.120 |
Why?
| | Computer-Assisted Instruction | 1 | 2017 | 70 | 0.120 |
Why?
| | Abscess | 1 | 2017 | 77 | 0.120 |
Why?
| | Phantoms, Imaging | 1 | 2017 | 159 | 0.120 |
Why?
| | Erythropoietin | 1 | 2017 | 100 | 0.120 |
Why?
| | Ultrasonography, Doppler | 2 | 2020 | 126 | 0.110 |
Why?
| | Palpation | 1 | 2015 | 15 | 0.110 |
Why?
| | Pulse | 1 | 2015 | 29 | 0.110 |
Why?
| | Calcium | 2 | 2004 | 1191 | 0.110 |
Why?
| | Adaptation, Physiological | 2 | 2017 | 560 | 0.110 |
Why?
| | Simulation Training | 1 | 2017 | 136 | 0.110 |
Why?
| | Receptor, Endothelin A | 1 | 2014 | 60 | 0.100 |
Why?
| | Femoral Artery | 1 | 2015 | 190 | 0.100 |
Why?
| | Vascular Diseases | 1 | 2017 | 252 | 0.100 |
Why?
| | Placenta | 1 | 2020 | 787 | 0.100 |
Why?
| | Teaching | 1 | 2015 | 237 | 0.090 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2014 | 192 | 0.090 |
Why?
| | Optic Nerve | 1 | 2013 | 67 | 0.090 |
Why?
| | PPAR gamma | 1 | 2013 | 182 | 0.090 |
Why?
| | Education, Medical, Undergraduate | 1 | 2015 | 208 | 0.090 |
Why?
| | Blood Flow Velocity | 2 | 2011 | 421 | 0.090 |
Why?
| | Students, Medical | 1 | 2017 | 378 | 0.090 |
Why?
| | Enzymes | 1 | 2011 | 60 | 0.090 |
Why?
| | Laser-Doppler Flowmetry | 1 | 2011 | 31 | 0.080 |
Why?
| | Students | 1 | 2016 | 652 | 0.080 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2013 | 181 | 0.080 |
Why?
| | Heart Rate | 1 | 2015 | 856 | 0.080 |
Why?
| | Infant, Small for Gestational Age | 1 | 2011 | 118 | 0.080 |
Why?
| | Iliac Artery | 1 | 2011 | 55 | 0.080 |
Why?
| | Angiostatic Proteins | 1 | 2010 | 4 | 0.080 |
Why?
| | Live Birth | 1 | 2011 | 81 | 0.080 |
Why?
| | Angiogenic Proteins | 1 | 2010 | 15 | 0.080 |
Why?
| | Case-Control Studies | 3 | 2017 | 3634 | 0.080 |
Why?
| | Stillbirth | 1 | 2011 | 82 | 0.080 |
Why?
| | Homeostasis | 1 | 2014 | 644 | 0.080 |
Why?
| | Female | 16 | 2020 | 79045 | 0.070 |
Why?
| | Curriculum | 1 | 2016 | 1074 | 0.070 |
Why?
| | Young Adult | 7 | 2020 | 14254 | 0.070 |
Why?
| | Humans | 16 | 2022 | 145783 | 0.070 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2014 | 2181 | 0.070 |
Why?
| | Ultrasonography, Prenatal | 1 | 2011 | 295 | 0.070 |
Why?
| | Sheep | 4 | 2004 | 876 | 0.070 |
Why?
| | Interleukin-1beta | 1 | 2010 | 390 | 0.070 |
Why?
| | Analysis of Variance | 1 | 2011 | 1300 | 0.070 |
Why?
| | Antioxidants | 1 | 2011 | 550 | 0.070 |
Why?
| | Models, Biological | 1 | 2015 | 1764 | 0.060 |
Why?
| | Adult | 11 | 2020 | 40881 | 0.060 |
Why?
| | Cross-Sectional Studies | 3 | 2017 | 5925 | 0.060 |
Why?
| | Premature Birth | 1 | 2011 | 390 | 0.060 |
Why?
| | Ginkgo biloba | 1 | 2005 | 10 | 0.060 |
Why?
| | Carbonic Anhydrase Inhibitors | 1 | 2005 | 14 | 0.060 |
Why?
| | Acetazolamide | 1 | 2005 | 26 | 0.050 |
Why?
| | Plant Preparations | 1 | 2005 | 37 | 0.050 |
Why?
| | Phytotherapy | 1 | 2005 | 74 | 0.050 |
Why?
| | Gene Expression Regulation | 1 | 2013 | 2601 | 0.050 |
Why?
| | Troponin I | 1 | 2004 | 73 | 0.050 |
Why?
| | Middle Aged | 3 | 2022 | 36309 | 0.050 |
Why?
| | Cytokines | 1 | 2010 | 2069 | 0.050 |
Why?
| | Indians, South American | 2 | 2013 | 23 | 0.040 |
Why?
| | Sensitivity and Specificity | 2 | 2017 | 2000 | 0.040 |
Why?
| | Electric Stimulation | 2 | 2004 | 277 | 0.040 |
Why?
| | Cohort Studies | 3 | 2020 | 6033 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2017 | 3418 | 0.030 |
Why?
| | Colforsin | 1 | 1997 | 47 | 0.030 |
Why?
| | Isoproterenol | 1 | 1997 | 96 | 0.030 |
Why?
| | Adrenergic beta-Agonists | 1 | 1997 | 92 | 0.030 |
Why?
| | Isradipine | 1 | 1997 | 3 | 0.030 |
Why?
| | Heart Ventricles | 2 | 2004 | 756 | 0.030 |
Why?
| | Ryanodine | 1 | 1997 | 15 | 0.030 |
Why?
| | Cyclic AMP | 1 | 1997 | 208 | 0.030 |
Why?
| | Organ Size | 1 | 1997 | 461 | 0.030 |
Why?
| | Equipment Failure Analysis | 1 | 2017 | 124 | 0.030 |
Why?
| | Ryanodine Receptor Calcium Release Channel | 1 | 1997 | 72 | 0.030 |
Why?
| | Reference Values | 1 | 1997 | 798 | 0.030 |
Why?
| | Calcium Channels | 1 | 1997 | 157 | 0.030 |
Why?
| | Calcium Channels, L-Type | 1 | 1997 | 117 | 0.030 |
Why?
| | In Vitro Techniques | 1 | 1997 | 1049 | 0.030 |
Why?
| | Equipment Design | 1 | 2017 | 525 | 0.030 |
Why?
| | Muscle Proteins | 1 | 1997 | 243 | 0.030 |
Why?
| | California | 1 | 2017 | 473 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 849 | 0.030 |
Why?
| | Receptor, Endothelin B | 1 | 2014 | 43 | 0.030 |
Why?
| | Radiology | 1 | 2017 | 174 | 0.030 |
Why?
| | Ventricular Function, Right | 1 | 1997 | 297 | 0.030 |
Why?
| | Receptors, Endothelin | 1 | 2014 | 48 | 0.030 |
Why?
| | Oxygen Consumption | 1 | 1997 | 719 | 0.030 |
Why?
| | Universities | 1 | 2016 | 445 | 0.030 |
Why?
| | Mentoring | 1 | 2016 | 166 | 0.020 |
Why?
| | Ventricular Function, Left | 1 | 1997 | 544 | 0.020 |
Why?
| | Tibet | 1 | 2013 | 23 | 0.020 |
Why?
| | Gene Frequency | 1 | 2014 | 489 | 0.020 |
Why?
| | South America | 1 | 2013 | 56 | 0.020 |
Why?
| | Intracranial Hypertension | 1 | 2013 | 42 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2014 | 371 | 0.020 |
Why?
| | Intracranial Pressure | 1 | 2013 | 65 | 0.020 |
Why?
| | Linear Models | 1 | 2014 | 849 | 0.020 |
Why?
| | Gene Regulatory Networks | 1 | 2014 | 318 | 0.020 |
Why?
| | Geography | 1 | 2011 | 187 | 0.020 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2014 | 456 | 0.020 |
Why?
| | Infant, Newborn | 2 | 2013 | 6465 | 0.020 |
Why?
| | Selection, Genetic | 1 | 2013 | 263 | 0.020 |
Why?
| | Placenta Growth Factor | 1 | 2010 | 26 | 0.020 |
Why?
| | Hemoglobins | 1 | 2013 | 386 | 0.020 |
Why?
| | Pregnancy Proteins | 1 | 2010 | 36 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2010 | 74 | 0.020 |
Why?
| | Acute Disease | 1 | 2013 | 1036 | 0.020 |
Why?
| | Interleukin-4 | 1 | 2010 | 207 | 0.020 |
Why?
| | Incidence | 1 | 2017 | 2934 | 0.020 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2010 | 253 | 0.020 |
Why?
| | Genotype | 1 | 2014 | 1857 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 528 | 0.020 |
Why?
| | Pedigree | 1 | 2010 | 515 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2017 | 2968 | 0.020 |
Why?
| | Animals | 4 | 2004 | 38101 | 0.020 |
Why?
| | Up-Regulation | 1 | 2011 | 848 | 0.020 |
Why?
| | Interleukin-10 | 1 | 2010 | 311 | 0.020 |
Why?
| | Prognosis | 1 | 2017 | 4330 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2014 | 1454 | 0.020 |
Why?
| | Chronic Disease | 1 | 2013 | 1812 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 5428 | 0.020 |
Why?
| | Clinical Competence | 1 | 2015 | 1247 | 0.020 |
Why?
| | Male | 4 | 2017 | 73010 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2010 | 780 | 0.010 |
Why?
| | Health Status | 1 | 2011 | 835 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2010 | 1217 | 0.010 |
Why?
| | Biomarkers | 1 | 2017 | 4302 | 0.010 |
Why?
| | Colorado | 1 | 2015 | 4556 | 0.010 |
Why?
| | Egtazic Acid | 1 | 2004 | 37 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 2005 | 428 | 0.010 |
Why?
| | Cardiac Output | 1 | 2004 | 179 | 0.010 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 1 | 2004 | 125 | 0.010 |
Why?
| | Actin Cytoskeleton | 1 | 2004 | 103 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2010 | 2399 | 0.010 |
Why?
| | Risk Assessment | 1 | 2010 | 3752 | 0.010 |
Why?
| | Infant | 1 | 2014 | 10091 | 0.010 |
Why?
| | Double-Blind Method | 1 | 2005 | 2064 | 0.010 |
Why?
| | Phosphorylation | 1 | 2004 | 1708 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2013 | 11794 | 0.010 |
Why?
| | Prospective Studies | 1 | 2010 | 8078 | 0.010 |
Why?
| | Risk Factors | 1 | 2010 | 10919 | 0.010 |
Why?
| | Adolescent | 1 | 2013 | 22577 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1997 | 2028 | 0.010 |
Why?
| | Aged | 1 | 2013 | 26217 | 0.010 |
Why?
| | Oxygen | 1 | 1997 | 981 | 0.010 |
Why?
|
|
Browne's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|